ArticleDiabetes & metabolic syndrome
Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
Article in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 59 citations in OpenAlex.
- Investigating the role of opium consumption in the severity, and outcome of COVID-19.BMC infectious diseases · 2026Article
- Epigenetic perspectives associated with COVID-19 infection and related cytokine storm: an updated review.Infection · 2023Review
- Ketogenic Diet and Ketone Bodies as Clinical Support for the Treatment of SARS-CoV-2-Review of the Evidence.Viruses · 2023Review
- Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells.Biomolecules · 2023Article
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- Review
- Andrographolide induces anti-SARS-CoV-2 response through host-directed mechanism: anFuture virology · 2022Article
- Increasing opium use in Iran in response to unsubstantiated rumors that it protects against COVID-19.Addiction (Abingdon, England) · 2022Article
- Opioid-Use, COVID-19 Infection, and Their Neurological Implications.Frontiers in neurology · 2022Review
- Anaesthesia drugs, SARS-CoV-2, and the sigma-1 receptor: a complex affair. Comment on Br J Anaesth 2021; 127: e32-4.British journal of anaesthesia · 2021Article
- Therapeutic potential of long-acting opioids and opioid antagonists for SARS-CoV-2 infection.British journal of anaesthesia · 2021Article
- Predicting respiratory failure in patients infected by SARS-CoV-2 by admission sex-specific biomarkers.Biology of sex differences · 2021Article
- SARS-CoV-2 spike protein binding selectively accelerates substrate-specific catalytic activity of ACE2.Journal of biochemistry · 2021Article
- Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.Reviews in medical virology · 2021Review
- Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- ACE2 correlates with immune infiltrates in colon adenocarcinoma: Implication for COVID-19.International immunopharmacology · 2021Article
- The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications.Heart, lung & circulation · 2021Review
- Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia.Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Article
- Article
- Soluble ACE2 as a potential therapy for COVID-19.American journal of physiology. Cell physiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) is a global health emergency that poses a significant threat to world people's health. This outbreak causes major challenges to healthcare systems. Given the lack of effective treatments or vaccine for it, the identification of novel and safe drugs against COVID-19 infection is an urgent need. Angiotensin-converting enzyme 2 (ACE2) is not only an entry receptor of the SARS-CoV-2 virus, the virus that causes COVID-19, but also can protect from lung injury. In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). Further clinical trials in this regard can reveal a more definite conclusion against the COVID-19 disaster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.